Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7795081 PK Study in Renal Impairment
NCT07741604Phase 1Recruiting
- Sponsor
- Roche
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7795081 in obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Roche. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
RO7795081
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07741604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07741604.